The CAV1 Knockout 769-P Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout population derived from the 769-P clear cell renal cell carcinoma line. This heterogeneous pool of CAV1-deficient cells enables loss-of-function analysis of caveolin-1 without the constraints of single-cell cloning, providing a robust model for functional studies.
The parental 769-P cell line originates from a primary human clear cell renal cell carcinoma and serves as a well-characterized cancerous kidney epithelial model. It retains hallmark features of ccRCC, including deregulated growth signaling and tumorigenic capacity, making it an appropriate host for interrogating gene function in renal cancer.
Caveolin-1 is the main scaffolding protein of caveolae, directly binding and inhibiting signaling effectors such as EGFR, Src, and eNOS. Its expression is regulated by upstream factors including TGF-beta, SREBP, and cholesterol. Disruption of CAV1 relieves this inhibition, leading to hyperactivation of downstream AKT, ERK1/2, and STAT3 pathways. Consequently, the knockout alters MAPK/ERK and PI3K/AKT signaling, impacting proliferation, survival, and cytoskeletal organization via Rho GTPase and integrin crosstalk.
In 769-P cells, caveolin-1 frequently exhibits tumor-suppressive properties, and its loss is associated with enhanced metastatic potential and therapy resistance in ccRCC. This knockout model therefore allows detailed examination of CAV1??s context-dependent roles in epithelial-to-mesenchymal transition, migration, and drug sensitivity, directly addressing key questions in renal carcinoma biology.
Researchers can apply this polyclonal knockout pool to tumor suppressor research, caveolae biology, and signal transduction studies. Typical workflows include Western blotting for CAV1, phospho-signaling analysis for AKT and ERK1/2, Transwell migration/invasion assays, and proliferation measurements. This versatile tool supports dissection of caveolin-1-dependent regulatory networks in ccRCC. For further information, please contact Ascent Research.
